Baghi M - Search Results

1

Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.

Baghi M, Hambek M, May A, Radeloff A, Gstoettner W, Knecht R. Baghi M, et al. Anticancer Res. 2006 Jan-Feb;26(1B):559-63. Anticancer Res. 2006. PMID: 16739320 Free article. Clinical Trial.

2

Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.

Baghi M, Wagenblast J, Hambek M, Moertel S, Gstoettner W, Strebhardt K, Knecht R. Baghi M, et al. Clin Otolaryngol. 2008 Jun;33(3):245-51. doi: 10.1111/j.1749-4486.2008.01702.x. Clin Otolaryngol. 2008. PMID: 18559031

3

EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.

Knecht R, Peters S, Solbach C, Baghi M, Gstöttner W, Hambek M. Knecht R, et al. Among authors: baghi m. Anticancer Res. 2003 Nov-Dec;23(6C):4789-95. Anticancer Res. 2003. PMID: 14981927

4

EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.

Knecht R, Peters S, Hambek M, Solbach C, Baghi M, Gstöttner W, Hambek M. Knecht R, et al. Among authors: baghi m. Adv Otorhinolaryngol. 2005;62:81-91. doi: 10.1159/000082475. Adv Otorhinolaryngol. 2005. PMID: 15608420

5

STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.

Hambek M, Baghi M, Strebhardt K, May A, Adunka O, Gstöttner W, Knecht R. Hambek M, et al. Among authors: baghi m. Anticancer Res. 2004 Nov-Dec;24(6):3881-6. Anticancer Res. 2004. PMID: 15736426 Free article.

6

The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers.

Baghi M, Mack MG, Hambek M, Rieger J, Vogl T, Gstoettner W, Knecht R. Baghi M, et al. Anticancer Res. 2005 Sep-Oct;25(5):3665-70. Anticancer Res. 2005. PMID: 16101198 Free article.

7

Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).

Hambek M, Baghi M, Baumaun H, Strebhardt K, Adunka O, Gstöttner W, Knecht R. Hambek M, et al. Among authors: baghi m. Anticancer Res. 2005 May-Jun;25(3B):1871-5. Anticancer Res. 2005. PMID: 16158919 Free article.

8

Reduction of cisplatin dosage by ZD 1839.

Hambek M, Baghi M, Strebhardt K, Baumann H, Gstöttner W, Knecht R. Hambek M, et al. Among authors: baghi m. Anticancer Res. 2005 Nov-Dec;25(6B):3985-8. Anticancer Res. 2005. PMID: 16309188 Free article.

9

Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.

Hambek M, Werner C, Baghi M, Gstöttner W, Knecht R. Hambek M, et al. Among authors: baghi m. Anticancer Res. 2006 Mar-Apr;26(2A):1091-5. Anticancer Res. 2006. PMID: 16619511 Free article.

10

A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).

Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R. Baghi M, et al. Anticancer Res. 2006 Jan-Feb;26(1B):585-90. Anticancer Res. 2006. PMID: 16739325 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters